$CURX

Curanex Pharmaceuticals Inc (CURX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Legal Proceedings On July 23, 2026, Daymond Morales, et al., filed a putative securities class action in the Supreme Court of the State of New York, New York County (Index No. 159271/2026), against the Company and its underwriters Dominari Securities LLC,

Curanex Pharmaceuticals Inc. (CURX) completed its IPO in 2025, raising $17.25 million, but reported no revenue and a net loss of $4.2 million due to increased R&D and general & administrative expenses. Its flagship product, Phyto-N, is in preclinical development, with an IND submission for ulcerative colitis planned for late 2026. The company faces ongoing material weaknesses in internal controls and risks related to its Nasdaq listing.

Curanex Pharmaceuticals Inc. has appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board, enhancing its expertise as it prepares for an Investigational New Drug (IND) filing for its lead candidate, Phyto-N. The company, which focuses on botanical drugs for inflammatory diseases, aims for IND submission and Phase I clinical trials in Q4 2026. Despite recent stock declines, Curanex (NASDAQ:CURX) shows financial stability with strong liquidity and more cash than debt.

Curanex Pharmaceuticals Inc. announced the successful completion of a GMP-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. This milestone is crucial for its planned Investigational New Drug (IND) submission for ulcerative colitis, targeted for Q4 2026. The company is now advancing GLP toxicology and pharmacokinetic studies to support the regulatory submission.

Curanex (Nasdaq: CURX) has completed a GMP-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N, as it prepares for an Investigational New Drug (IND) submission for ulcerative colitis. The company is targeting a Q4 2026 IND submission and is advancing GLP toxicology and pharmacokinetic studies. This milestone follows positive non-GLP safety studies and positions Curanex for future clinical development.

Jericho, New York, Sept. 12, 2025 ( GLOBE NEWSWIRE ) -- Curanex Pharmaceuticals Inc. ( Nasdaq: CURX ) ( "Curanex" or the "Company" ) , a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced that Dominari ...